Standardized care documentation for polycythemia vera
Part of Blood & lymphatic, Cancer clinical trials.
This trial aims to improve how doctors document and assess care for patients with polycythemia vera (PV), a rare blood disorder. It may lead to more consistent and better-informed treatment decisions for people living with PV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a doctor (hematologist or medical oncologist) at a Mass General Brigham clinic.
- You treat at least one patient with polycythemia vera in your clinic.
- You use the EPIC electronic medical record system for your patient notes.
- You have an outpatient clinic at Mass General Brigham.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study asks doctors how they diagnose and treat polycythaemia vera (PV), a blood condition where the body makes too many red blood cells. Your answers will help improve care for future patients.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This study follows people with high red blood cell counts (erythrocytosis) who are seen at a blood specialty clinic. The goal is to track their health over time to learn more about this condition and how it affects patients.
This study tests a new medicine called AG-236 in people with polycythemia vera (PV), a condition where the body makes too many red blood cells. The trial aims to see if AG-236 can reduce the need for phlebotomies (removing blood to lower red blood cell count) and help control the disease.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This study watches how a blood condition called essential thrombocythemia (ET) changes into another condition called polycythemia vera (PV) in people with a specific JAK2 mutation. It aims to learn more about these changes and what happens to patients over time.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.